Logo image of BEAM

BEAM THERAPEUTICS INC (BEAM) Stock Fundamental Analysis

NASDAQ:BEAM - Nasdaq - US07373V1052 - Common Stock - Currency: USD

17.06  -0.38 (-2.18%)

After market: 17.11 +0.05 (+0.29%)

Fundamental Rating

3

Taking everything into account, BEAM scores 3 out of 10 in our fundamental rating. BEAM was compared to 559 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for BEAM as it has an excellent financial health rating, but there are worries on the profitability. BEAM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BEAM had negative earnings in the past year.
BEAM had a negative operating cash flow in the past year.
BEAM had negative earnings in each of the past 5 years.
BEAM had negative operating cash flow in 4 of the past 5 years.
BEAM Yearly Net Income VS EBIT VS OCF VS FCFBEAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M

1.2 Ratios

The Return On Assets of BEAM (-26.41%) is better than 71.56% of its industry peers.
With a decent Return On Equity value of -34.49%, BEAM is doing good in the industry, outperforming 74.24% of the companies in the same industry.
Industry RankSector Rank
ROA -26.41%
ROE -34.49%
ROIC N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
BEAM Yearly ROA, ROE, ROICBEAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BEAM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BEAM Yearly Profit, Operating, Gross MarginsBEAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K

More info and screens

7

2. Health

2.1 Basic Checks

BEAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BEAM has been increased compared to 1 year ago.
BEAM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BEAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BEAM Yearly Shares OutstandingBEAM Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
BEAM Yearly Total Debt VS Total AssetsBEAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

Based on the Altman-Z score of 1.37, we must say that BEAM is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.37, BEAM is doing good in the industry, outperforming 68.16% of the companies in the same industry.
BEAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.37
ROIC/WACCN/A
WACC16.01%
BEAM Yearly LT Debt VS Equity VS FCFBEAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 8.81 indicates that BEAM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.81, BEAM is in the better half of the industry, outperforming 72.99% of the companies in the same industry.
A Quick Ratio of 8.81 indicates that BEAM has no problem at all paying its short term obligations.
BEAM has a better Quick ratio (8.81) than 72.99% of its industry peers.
Industry RankSector Rank
Current Ratio 8.81
Quick Ratio 8.81
BEAM Yearly Current Assets VS Current LiabilitesBEAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for BEAM have decreased strongly by -158.99% in the last year.
Looking at the last year, BEAM shows a very negative growth in Revenue. The Revenue has decreased by -82.38% in the last year.
The Revenue has been growing by 401.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-158.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.48%
Revenue 1Y (TTM)-82.38%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%0.81%

3.2 Future

The Earnings Per Share is expected to grow by 6.24% on average over the next years.
The Revenue is expected to grow by 55.89% on average over the next years. This is a very strong growth
EPS Next Y-3.06%
EPS Next 2Y-1.49%
EPS Next 3Y-2.12%
EPS Next 5Y6.24%
Revenue Next Year3.1%
Revenue Next 2Y6.51%
Revenue Next 3Y9.94%
Revenue Next 5Y55.89%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BEAM Yearly Revenue VS EstimatesBEAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
BEAM Yearly EPS VS EstimatesBEAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BEAM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BEAM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BEAM Price Earnings VS Forward Price EarningsBEAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BEAM Per share dataBEAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

BEAM's earnings are expected to decrease with -2.12% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.49%
EPS Next 3Y-2.12%

More info and screens

0

5. Dividend

5.1 Amount

BEAM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEAM THERAPEUTICS INC

NASDAQ:BEAM (6/13/2025, 8:00:02 PM)

After market: 17.11 +0.05 (+0.29%)

17.06

-0.38 (-2.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners97.7%
Inst Owner Change24.95%
Ins Owners1.22%
Ins Owner Change11.59%
Market Cap1.72B
Analysts84.35
Price Target45.03 (163.95%)
Short Float %21%
Short Ratio8.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.25%
Min EPS beat(2)-0.76%
Max EPS beat(2)11.25%
EPS beat(4)3
Avg EPS beat(4)3.69%
Min EPS beat(4)-0.76%
Max EPS beat(4)11.25%
EPS beat(8)7
Avg EPS beat(8)42.08%
EPS beat(12)10
Avg EPS beat(12)32.53%
EPS beat(16)13
Avg EPS beat(16)23.89%
Revenue beat(2)1
Avg Revenue beat(2)11.69%
Min Revenue beat(2)-50.74%
Max Revenue beat(2)74.11%
Revenue beat(4)1
Avg Revenue beat(4)0.31%
Min Revenue beat(4)-50.74%
Max Revenue beat(4)74.11%
Revenue beat(8)3
Avg Revenue beat(8)188.99%
Revenue beat(12)7
Avg Revenue beat(12)153.83%
Revenue beat(16)10
Avg Revenue beat(16)265.65%
PT rev (1m)-8.58%
PT rev (3m)-9.06%
EPS NQ rev (1m)1.4%
EPS NQ rev (3m)8.85%
EPS NY rev (1m)0%
EPS NY rev (3m)2.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-13.69%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)-11.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.98
P/FCF N/A
P/OCF N/A
P/B 1.53
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)-4.61
EYN/A
EPS(NY)-4.72
Fwd EYN/A
FCF(TTM)-3.59
FCFYN/A
OCF(TTM)-3.49
OCFYN/A
SpS0.63
BVpS11.17
TBVpS11.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.41%
ROE -34.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.59%
ROA(5y)-26.65%
ROE(3y)-34.76%
ROE(5y)-45.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.47%
Cap/Sales 15.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.81
Quick Ratio 8.81
Altman-Z 1.37
F-Score3
WACC16.01%
ROIC/WACCN/A
Cap/Depr(3y)185.1%
Cap/Depr(5y)305.75%
Cap/Sales(3y)34.46%
Cap/Sales(5y)16398.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-158.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.48%
EPS Next Y-3.06%
EPS Next 2Y-1.49%
EPS Next 3Y-2.12%
EPS Next 5Y6.24%
Revenue 1Y (TTM)-82.38%
Revenue growth 3Y7.01%
Revenue growth 5Y401.62%
Sales Q2Q%0.81%
Revenue Next Year3.1%
Revenue Next 2Y6.51%
Revenue Next 3Y9.94%
Revenue Next 5Y55.89%
EBIT growth 1Y-137.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.42%
EBIT Next 3Y-8.63%
EBIT Next 5Y8.74%
FCF growth 1Y-2.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.91%
OCF growth 3YN/A
OCF growth 5YN/A